| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Description: ACY-1083 is a novel, potent, selective and brain-penetrant HDAC6 inhibitor with an IC50 of 3 nM. ACY-1083 shows 260-fold selectivity towards HDAC6 vs other HDACs. HDAC6 inhibition by ACY-1083 prevented cisplatin-induced mechanical allodynia, and also completely reversed already existing cisplatin-induced mechanical allodynia, spontaneous pain, and numbness. These findings were confirmed using the established HDAC6 inhibitor ACY-1215 (Ricolinostat), which is currently in clinical trials for cancer treatment. Mechanistically, treatment with the HDAC6 inhibitor increased α-tubulin acetylation in the peripheral nerve. In addition, HDAC6 inhibition restored the cisplatin-induced reduction in mitochondrial bioenergetics and mitochondrial content in the tibial nerve, indicating increased mitochondrial transport. At a later time point, dorsal root ganglion mitochondrial bioenergetics also improved. HDAC6 inhibition restored the loss of intraepidermal nerve fiber density in cisplatin-treated mice. These results demonstrate that pharmacological inhibition of HDAC6 completely reverses all the hallmarks of established cisplatin-induced peripheral neuropathy by normalization of mitochondrial function in dorsal root ganglia and nerve, and restoration of intraepidermal innervation. These results are especially promising because one of the HDAC6 inhibitors tested here is currently in clinical trials as an add-on cancer therapy, highlighting the potential for a fast clinical translation of these findings.
| ln Vitro |
Treatment with ACY-1083 (30 and 300 nM) greatly enhanced cell viability in a dose-dependent way [2].
|
|---|---|
| ln Vivo |
ACY-1083 (ip; 10 mg/kg; for 7 days) efficiently alleviates cisplatin-induced mechanical allodynia in C57BL/6J mice ACY-1083 (oral dose 3 mg/kg ACY-1083 for 7 days ) can reverse paclitaxel-induced mechanical allodynia in adult male SD rats. In mice treated 5 mg/kg ACY-1083 via intraperitoneal (ip) injection, the maximum plasma concentration (Cmax) was 936 ng/mL, the half-life (T1/2) was 3.5 hours, and the bioactive plasma exposure was 8 postdose. Hour.
|
| Cell Assay |
Cell Viability Assay [2]
Cell Types: Mouse Hippocampus (HT22) Cell Tested Concentrations: 30 and 300 nM Incubation Duration: Experimental Results: Cell viability was Dramatically improved. |
| Animal Protocol |
Animal/Disease Models: 8-10 weeks old adult male C57BL/6J mice [1]
Doses: 3 or 10 mg/kg Route of Administration: intraperitoneal (ip) injection; daily; 7 days Experimental Results: 10 mg/kg dose can alleviate cisplatin ( 2.3 mg/kg), but not the 3 mg/kg dose. Animal/Disease Models: Adult male Sprague Dawley rats [1] Doses: 3 mg/kg Route of Administration: Two oral doses per day for 7 days. Experimental Results: Paclitaxel (6 mg/kg or 12 mg/kg)-induced mechanical allodynia was reversed. |
| References |
|
| Molecular Formula |
C17H18F2N4O2
|
|---|---|
| Molecular Weight |
348.3472
|
| Exact Mass |
348.139
|
| CAS # |
1708113-43-2
|
| PubChem CID |
91844718
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.5
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
454
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC1(C([H])([H])C([H])([H])C(C2C([H])=C([H])C([H])=C([H])C=2[H])(C([H])([H])C1([H])[H])N([H])C1=NC([H])=C(C(N([H])O[H])=O)C([H])=N1)F
|
| InChi Key |
MRWCVKLVSWYIFO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H18F2N4O2/c18-17(19)8-6-16(7-9-17,13-4-2-1-3-5-13)22-15-20-10-12(11-21-15)14(24)23-25/h1-5,10-11,25H,6-9H2,(H,23,24)(H,20,21,22)
|
| Chemical Name |
2-[(4,4-difluoro-1-phenylcyclohexyl)amino]-N-hydroxypyrimidine-5-carboxamide
|
| Synonyms |
ACY-1083; ACY 1083; ACY1083
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~200 mg/mL (~574.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (14.35 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 5 mg/mL (14.35 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 5 mg/mL (14.35 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8707 mL | 14.3534 mL | 28.7068 mL | |
| 5 mM | 0.5741 mL | 2.8707 mL | 5.7414 mL | |
| 10 mM | 0.2871 mL | 1.4353 mL | 2.8707 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
 Structure, selectivity and pharmacokinetics of ACY-1083.Pain.2017 Jun;158(6):1126-1137. |
|---|
 Effect of repeated or prolonged ACY-1083 treatment on symptoms of cisplatin-induced peripheral neuropathy.Pain.2017 Jun;158(6):1126-1137. |
 ACY-1083 enhances mitochondrial bioenergetics and contents in the tibial nerve of cisplatin-treated mice.Pain.2017 Jun;158(6):1126-1137. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA